Table 1.
Characteristics of the study population
| Characteristic | N (%) |
|---|---|
| Age (years) | |
| ≤ 60 | 122 (63.9) |
| > 60 | 69 (36.1) |
| Sex | |
| Female | 85 (44.5) |
| Male | 106 (55.5) |
| BRAF mutational status | |
| V600E | 120 (62.8) |
| V600K | 15 (7.9) |
| V600R | 3 (1.6) |
| V600, not further specified | 53 (27.7) |
| Number of sites involved | |
| 1 | 31 (16.2) |
| 2 | 49 (25.7) |
| 3 | 45 (23.6) |
| 4 | 29 (15.2) |
| 5 | 20 (10.5) |
| 6 | 8 (4.2) |
| ≥ 7 | 9 (4.7) |
| M stagea | |
| M0 | 8 (4.2) |
| M1a | 18 (9.4) |
| M1b | 16 (8.4) |
| M1c | 149 (78.0) |
| Visceral metastasis | |
| No | 52 (27.2) |
| Yes | 139 (72.8) |
| CNS metastasis | |
| No | 131 (68.6) |
| Yes | 60 (31.4) |
| Liver metastasis | |
| No | 122 (63.9) |
| Yes | 69 (36.1) |
| Prior treatment regimens | |
| Anti-CTLA-4 | 20 (10.5) |
| Anti-PD-1 | 10 (5.2) |
| BRAFi ± MEKi | 0 (0.0) |
| Chemotherapy | 21 (11.0) |
| Radiotherapy | 49 (25.7) |
| Adjuvant interferon | 59 (30.9) |
| Treatment | |
| BRAFi monotherapy | 104 (54.5) |
| BRAFi + MEKi | 87 (45.5) |
| Dabrafenib | 22 (11.5) |
| Dabrafenib + trametinib | 47 (24.6) |
| Encorafenib | 3 (1.6) |
| Encorafenib + binimetinib | 14 (7.3) |
| Vemurafenib | 79 (41.4) |
| Vemurafenib + cobimetinib | 26 (13.6) |
| Line of treatment | |
| First line | 116 (60.7) |
| Second line | 57 (29.8) |
| Third line | 11 (5.8) |
| Fourth line | 7 (3.7) |
aAmerican Joint Committee on Cancer staging guideline for melanoma from 2009
BRAF B-Raf proto-oncogene, BRAFi BRAF inhibitor, CNS central nervous system, CTLA-4 cytotoxic T-lymphocyte-associated protein 4, MEK mitogen-activated protein kinase kinase, MEKi MEK inhibitor, PD-1 programmed cell death protein-1